Doga Turkkahraman1, Emel Saglar2, Tugce Karaduman2, Hatice Mergen2. 1. Department of Pediatric Endocrinology, Antalya Education and Research Hospital, Antalya, Turkey. drdoga@hotmail.com. 2. Department of Biology, Faculty of Science, Hacettepe University, Beytepe, Ankara, Turkey.
Abstract
BACKGROUND: Familial central diabetes insipidus (DI), usually an autosomal dominant disorder, is caused by mutations in arginine vasopressin-neurophysin II (AVP-NPII) gene that leads to aberrant preprohormone processing and gradual destruction of AVP-secreting cells. OBJECTIVE: To determine clinical and molecular characteristics of patients with familial central DI from two different Turkish families. MATERIALS AND METHODS: The diagnosis of central DI was established by 24-h urine collection, water deprivation test, and desmopressin challenge. To confirm the diagnosis of familial central DI, the entire coding region of AVP-NPII gene was amplified and sequenced. A total of eight affected patients and three unaffected healthy relatives from two families were studied. RESULTS: Genetic analysis revealed a previously reported heterozygous mutation (p.C98X) in family A, and a heterozygous novel mutation (p.G45C) in family B, both detected in exon 2 of AVP-NPII gene. When we compared the clinical characteristics of the two families, it was noticed that as the age of onset of symptoms in family A ranges between 4 and 7 years, it was <1 year in family B. Additionally, pituitary bright spot was present in the affected siblings, but absent in their affected parents. CONCLUSION: Familial central DI is a progressive disease, and age of onset of symptoms can differ depending on the mutation. Bright spot on pituitary MRI might be present at onset, but become invisible over time. Genetic testing and appropriate counseling should be given in familial cases of central DI to ensure adequate treatment, and to avoid chronic water deprivation that might result in growth retardation in childhood.
BACKGROUND:Familial central diabetes insipidus (DI), usually an autosomal dominant disorder, is caused by mutations in arginine vasopressin-neurophysin II (AVP-NPII) gene that leads to aberrant preprohormone processing and gradual destruction of AVP-secreting cells. OBJECTIVE: To determine clinical and molecular characteristics of patients with familial central DI from two different Turkish families. MATERIALS AND METHODS: The diagnosis of central DI was established by 24-h urine collection, water deprivation test, and desmopressin challenge. To confirm the diagnosis of familial central DI, the entire coding region of AVP-NPII gene was amplified and sequenced. A total of eight affected patients and three unaffected healthy relatives from two families were studied. RESULTS: Genetic analysis revealed a previously reported heterozygous mutation (p.C98X) in family A, and a heterozygous novel mutation (p.G45C) in family B, both detected in exon 2 of AVP-NPII gene. When we compared the clinical characteristics of the two families, it was noticed that as the age of onset of symptoms in family A ranges between 4 and 7 years, it was <1 year in family B. Additionally, pituitary bright spot was present in the affected siblings, but absent in their affected parents. CONCLUSION: Familial central DI is a progressive disease, and age of onset of symptoms can differ depending on the mutation. Bright spot on pituitary MRI might be present at onset, but become invisible over time. Genetic testing and appropriate counseling should be given in familial cases of central DI to ensure adequate treatment, and to avoid chronic water deprivation that might result in growth retardation in childhood.
Entities:
Keywords:
AVP-NPII gene; Familial central diabetes insipidus; Mutation
Authors: L Q Chen; J P Rose; E Breslow; D Yang; W R Chang; W F Furey; M Sax; B C Wang Journal: Proc Natl Acad Sci U S A Date: 1991-05-15 Impact factor: 11.205
Authors: Theron A Russell; Masafumi Ito; Mika Ito; Richard N Yu; Fred A Martinson; Jeffrey Weiss; J Larry Jameson Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Gabriela Hrčková; Viktor Jankó; Jitka Kytnarová; Michaela Čižmárová; Markéta Tesařová; Ľudmila Košťálová; Daniela Virgová; Tomáš Dallos; Václav Hána; Jan Lebl; Jiří Zeman; László Kovács Journal: Eur J Pediatr Date: 2016-08-18 Impact factor: 3.183